1. Home
  2. WEYS vs DSGN Comparison

WEYS vs DSGN Comparison

Compare WEYS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WEYS
  • DSGN
  • Stock Information
  • Founded
  • WEYS 1906
  • DSGN 2017
  • Country
  • WEYS United States
  • DSGN United States
  • Employees
  • WEYS N/A
  • DSGN N/A
  • Industry
  • WEYS Apparel
  • DSGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • WEYS Consumer Staples
  • DSGN Health Care
  • Exchange
  • WEYS Nasdaq
  • DSGN Nasdaq
  • Market Cap
  • WEYS 337.8M
  • DSGN 353.9M
  • IPO Year
  • WEYS N/A
  • DSGN 2021
  • Fundamental
  • Price
  • WEYS $38.03
  • DSGN $6.25
  • Analyst Decision
  • WEYS
  • DSGN Hold
  • Analyst Count
  • WEYS 0
  • DSGN 3
  • Target Price
  • WEYS N/A
  • DSGN $7.00
  • AVG Volume (30 Days)
  • WEYS 21.5K
  • DSGN 208.4K
  • Earning Date
  • WEYS 11-05-2024
  • DSGN 11-07-2024
  • Dividend Yield
  • WEYS 2.71%
  • DSGN N/A
  • EPS Growth
  • WEYS N/A
  • DSGN N/A
  • EPS
  • WEYS 3.02
  • DSGN N/A
  • Revenue
  • WEYS $290,409,000.00
  • DSGN N/A
  • Revenue This Year
  • WEYS N/A
  • DSGN N/A
  • Revenue Next Year
  • WEYS N/A
  • DSGN N/A
  • P/E Ratio
  • WEYS $12.60
  • DSGN N/A
  • Revenue Growth
  • WEYS N/A
  • DSGN N/A
  • 52 Week Low
  • WEYS $27.05
  • DSGN $2.25
  • 52 Week High
  • WEYS $41.05
  • DSGN $7.77
  • Technical
  • Relative Strength Index (RSI)
  • WEYS 61.32
  • DSGN 52.38
  • Support Level
  • WEYS $35.12
  • DSGN $5.55
  • Resistance Level
  • WEYS $37.53
  • DSGN $6.45
  • Average True Range (ATR)
  • WEYS 1.40
  • DSGN 0.56
  • MACD
  • WEYS 0.27
  • DSGN -0.04
  • Stochastic Oscillator
  • WEYS 97.03
  • DSGN 57.67

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale and the North American retail segment. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: